
Sign up to save your podcasts
Or


About 10% to 15% of breast cancers are triple-negative. This means they don’t have receptors for the hormones estrogen or progesterone, and don’t have too many HER2 proteins. So, hormonal therapy medicines and medicines that target the HER2 protein aren’t effective against triple-negative breast cancer.
Chemotherapy and immunotherapy are commonly used to treat triple-negative disease. But scientists are working diligently to develop new treatments that are more precise and targeted.
Triple-negative breast cancer expert Dr. Lisa Carey explains the latest research.
Listen to the episode to hear Dr. Carey discuss:
By Breastcancer.org4.3
4242 ratings
About 10% to 15% of breast cancers are triple-negative. This means they don’t have receptors for the hormones estrogen or progesterone, and don’t have too many HER2 proteins. So, hormonal therapy medicines and medicines that target the HER2 protein aren’t effective against triple-negative breast cancer.
Chemotherapy and immunotherapy are commonly used to treat triple-negative disease. But scientists are working diligently to develop new treatments that are more precise and targeted.
Triple-negative breast cancer expert Dr. Lisa Carey explains the latest research.
Listen to the episode to hear Dr. Carey discuss:

22,010 Listeners

1,095 Listeners

2,041 Listeners

1,684 Listeners

2,621 Listeners

3,527 Listeners

9,242 Listeners

53 Listeners

4,379 Listeners

331 Listeners

373 Listeners

20,294 Listeners

1,183 Listeners

117 Listeners

30 Listeners